These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36459208)

  • 21. Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas.
    Goschzik T; Mynarek M; Doerner E; Schenk A; Spier I; Warmuth-Metz M; Bison B; Obrecht D; Struve N; Kortmann RD; Schmid M; Aretz S; Rutkowski S; Pietsch T
    Acta Neuropathol; 2022 Dec; 144(6):1143-1156. PubMed ID: 36181537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteomic profiling of medulloblastoma reveals novel proteins differentially expressed within each molecular subgroup.
    Narayan V; Jaiswal J; Sugur H; Sd S; Rao S; Chatterjee A; Gowda H; A A; Somanna S; Santosh V
    Clin Neurol Neurosurg; 2020 Sep; 196():106028. PubMed ID: 32580068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort.
    Pietsch T; Schmidt R; Remke M; Korshunov A; Hovestadt V; Jones DT; Felsberg J; Kaulich K; Goschzik T; Kool M; Northcott PA; von Hoff K; von Bueren AO; Friedrich C; Mynarek M; Skladny H; Fleischhack G; Taylor MD; Cremer F; Lichter P; Faldum A; Reifenberger G; Rutkowski S; Pfister SM
    Acta Neuropathol; 2014 Jul; 128(1):137-49. PubMed ID: 24791927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
    Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
    J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical Surrogates for Molecular Stratification in Medulloblastoma.
    Chinnam D; Saraswati A; Jogunoori S; Verma A; Kiran T; Salunke P; Gupta N; Kumar N; Madan R; Radotra BD; Gupta K
    Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):561-568. PubMed ID: 37471625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
    Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC
    Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
    Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study.
    Schwalbe EC; Lindsey JC; Danilenko M; Hill RM; Crosier S; Ryan SL; Williamson D; Castle J; Hicks D; Kool M; Milde T; Korshunov A; Pfister SM; Bailey S; Clifford SC
    Neuro Oncol; 2024 Oct; ():. PubMed ID: 39377358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Classification of Medulloblastoma.
    Kijima N; Kanemura Y
    Neurol Med Chir (Tokyo); 2016 Nov; 56(11):687-697. PubMed ID: 27238212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.
    Kool M; Korshunov A; Remke M; Jones DT; Schlanstein M; Northcott PA; Cho YJ; Koster J; Schouten-van Meeteren A; van Vuurden D; Clifford SC; Pietsch T; von Bueren AO; Rutkowski S; McCabe M; Collins VP; Bäcklund ML; Haberler C; Bourdeaut F; Delattre O; Doz F; Ellison DW; Gilbertson RJ; Pomeroy SL; Taylor MD; Lichter P; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):473-84. PubMed ID: 22358457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MRI Radiogenomics of Pediatric Medulloblastoma: A Multicenter Study.
    Zhang M; Wong SW; Wright JN; Wagner MW; Toescu S; Han M; Tam LT; Zhou Q; Ahmadian SS; Shpanskaya K; Lummus S; Lai H; Eghbal A; Radmanesh A; Nemelka J; Harward S; Malinzak M; Laughlin S; Perreault S; Braun KRM; Lober RM; Cho YJ; Ertl-Wagner B; Ho CY; Mankad K; Vogel H; Cheshier SH; Jacques TS; Aquilina K; Fisher PG; Taylor M; Poussaint T; Vitanza NA; Grant GA; Pfister S; Thompson E; Jaju A; Ramaswamy V; Yeom KW
    Radiology; 2022 Aug; 304(2):406-416. PubMed ID: 35438562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular pathological insights reveal a high number of unfavorable risk patients among children treated for medulloblastoma and CNS-PNET in Oslo 2005-2017.
    Niehusmann P; Stensvold E; Leske H; Pietsch T; Goschzik T; Gielen GH; Due-Tønnessen B; Frič R; Nilssen Y; Brandal P
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29736. PubMed ID: 35570402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of Ki-67 index in adult medulloblastoma after accounting for molecular subgroup: a retrospective clinical and molecular analysis.
    Zhao F; Zhang J; Li P; Zhou Q; Zhang S; Zhao C; Wang B; Yang Z; Li C; Liu P
    J Neurooncol; 2018 Sep; 139(2):333-340. PubMed ID: 29687281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicomorphological and molecular analysis of medulloblastoma and association with survival: A single tertiary care center experience.
    Badiger S; Gudipati A; Uppin M; Konatam ML; Yeramneni VK; Bhattacharjee S; Saradhi MV; Patnaik S; Irukulla M
    J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S592-S602. PubMed ID: 38384024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of molecular subgroups in survival outcome for children with medulloblastoma in Malaysia.
    Rajagopal R; Teng AJ; Jawin V; Wong OL; Mahsin H; Abd Rani NH; Yap TY; Gunasagaran K; Thevarajah A; Yeoh SL; Ong GB; Ariffin H; Jones D; Bouffet E; Gottardo NG
    Front Oncol; 2023; 13():1278611. PubMed ID: 37920166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome.
    Kolodziejczak AS; Guerrini-Rousseau L; Planchon JM; Ecker J; Selt F; Mynarek M; Obrecht D; Sill M; Autry RJ; Stutheit-Zhao E; Hirsch S; Amouyal E; Dufour C; Ayrault O; Torrejon J; Waszak SM; Ramaswamy V; Pentikainen V; Demir HA; Clifford SC; Schwalbe EC; Massimi L; Snuderl M; Galbraith K; Karajannis MA; Hill K; Li BK; Walsh M; White CL; Redmond S; Loizos L; Jakob M; Kordes UR; Schmid I; Hauer J; Blattmann C; Filippidou M; Piccolo G; Scheurlen W; Farrag A; Grund K; Sutter C; Pietsch T; Frank S; Schewe DM; Malkin D; Ben-Arush M; Sehested A; Wong TT; Wu KS; Liu YL; Carceller F; Mueller S; Stoller S; Taylor MD; Tabori U; Bouffet E; Kool M; Sahm F; von Deimling A; Korshunov A; von Hoff K; Kratz CP; Sturm D; Jones DTW; Rutkowski S; van Tilburg CM; Witt O; Bougeard G; Pajtler KW; Pfister SM; Bourdeaut F; Milde T
    Neuro Oncol; 2023 Dec; 25(12):2273-2286. PubMed ID: 37379234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid diagnosis of medulloblastoma molecular subgroups.
    Schwalbe EC; Lindsey JC; Straughton D; Hogg TL; Cole M; Megahed H; Ryan SL; Lusher ME; Taylor MD; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
    Clin Cancer Res; 2011 Apr; 17(7):1883-94. PubMed ID: 21325292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk Stratification of Childhood Medulloblastoma Using Integrated Diagnosis: Discrepancies with Clinical Risk Stratification.
    Cho HW; Lee H; Ju HY; Yoo KH; Koo HH; Lim DH; Sung KW; Shin HJ; Suh YL; Lee JW
    J Korean Med Sci; 2022 Feb; 37(7):e59. PubMed ID: 35191235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
    Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
    Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression.
    Korshunov A; Okonechnikov K; Stichel D; Schrimpf D; Delaidelli A; Tonn S; Mynarek M; Sievers P; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M
    Acta Neuropathol; 2022 Aug; 144(2):339-352. PubMed ID: 35771282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.